Placid Jover - 05 Mar 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Signature
/s/ Dov Bergwerk as attorney-in-fact for Placid Jover
Issuer symbol
TEVA
Transactions as of
05 Mar 2025
Net transactions value
$0
Form type
4
Filing time
07 Mar 2025, 16:07:32 UTC
Previous filing
05 Aug 2024
Next filing
05 Aug 2025

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +56,603 $0.000000 56,603 05 Mar 2025 Ordinary Shares 56,603 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

Executive Vice President, Chief Human Resources Officer.